



Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD)

doi: [10.5281/zenodo.5014074](https://doi.org/10.5281/zenodo.5014074)

COMMUNITY OVERVIEW

The Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease. The community maintains several working groups that collaborate around data processing, analysis, and publications; making data and tools available to the rest of the research community through an online platform. The goal of the second iteration of this transformative partnership is to expand the open-science, precompetitive enterprise and enable a true precision medicine approach to target and biomarker discovery.

► Website: adknowledgeportal.org

KEYWORDS

Disciplines / skills

- INTERDISCIPLINARY
- DATA SCIENCE
- SOFTWARE AND CODE
- HEALTH / MEDICINE
- BIOTECHNOLOGY
- SYSTEMS BIOLOGY


Programming and goals

- STANDARD SETTING
- INFRASTRUCTURE DEVELOPMENT
- OPEN SCIENCE
- KNOWLEDGE GENERATION
- OUTREACH AND EXTERNAL COMMUNICATIONS

Stakeholder relationships

- MULTI-STAKEHOLDER
- INDUSTRY-ACADEMIA

COMMUNITY BASICS




COMMUNITY STRUCTURE

Community Management

Community management is provided by a full-time **Communications Manager** with additional 4.0 FTE split between the **Data Coordination Center** and **AD Translational Research** teams at Sage Bionetworks, who help generate content for the newsletter and gather data use statistics.



Members




Community Configuration





PROGRAMMING

Programming includes annual face-to-face meetings, monthly progress report webinars, and regular working group meetings focusing on different scientific areas. Communications include newsletters every two months, a quarterly webinar series, a regularly updated news page and blog posts, and a curated social media presence with feature stories, interviews, and videos. The community connects via an internal data management and collaboration platform, and some staff members communicate via Slack.



THE COMMUNITY PARTICIPATION MODEL

The CSCCE Community Participation Model describes four modes of member engagement that can occur within a community – CONVEY/CONSUME, CONTRIBUTE, COLLABORATE, and CO-CREATE – and one that can occur both inside and outside of it: CHAMPION. All modes may be present at once, with some members interacting in multiple modes – or a community may have member engagement that falls into only some of the modes described. The model enables the mapping of community member behaviors to programming and other infrastructural support that the community manager, convening organization, or funder may provide to the community.

► For more information, see the [CSCCE community participation model](#).



COMMUNITY CHAMPIONS

AMP-AD is currently planning a champions program. At the moment, members may informally act as champions in the following ways:



MAINTAIN

- act as informal community managers



GROW

- reshare resources
- represent the community at external events



EVOLVE

- propose and/or lead subgroups



CHAMPIONS take on additional activities to support or advance the community. They are sometimes described as emergent leaders.

COMMUNITY TOOLBOX

Communications

Email	Zoom
MailChimp	GitHub
Blog	Slack
Twitter	

Productivity

R	Google Analytics
Google Drive	GitHub

Community platform

Slack	Synapse (a data management & collaboration platform)
GitHub	



Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD)

doi: [10.5281/zenodo.5014074](https://doi.org/10.5281/zenodo.5014074)

► CSCCE Community Profile

OUTPUTS & EVALUATION

Success looks like the broad and rapid distribution of research, with open science practices and big data driven approaches used to bring a precision medicine approach to the discovery of targets and biomarkers.



Successes over the last year

Building resilience and adaptability throughout the chaos of COVID-19 (e.g., well attended and engaging face-to-face meetings conducted virtually). The community also launched a second iteration of the program with a new set of private partners (listed at right).

- **Growth** - added new working groups
- **Growth** - launched new program or project
- **Growth** - added new members
- **Activities** - created community outputs together
- **Activities** - an in-person or virtual event
- **Funding** - added a new revenue stream
- **Value** - external recognition of the community's impact



Evaluation and Reporting

- Metrics and data use statistics for members and leadership
- Monthly progress report webinars for members and leadership



Opportunities

More engagement from collaborators and funding partners; increased impact on individual investigators (e.g., career trajectory).

- **Growth** - new working groups
- **Growth** - launch new program or project
- **Engagement** - increase member activity
- **Engagement** - more members acting as champions
- **Activities** - create community outputs together
- **Activities** - host conference(s) / workshops
- **Value** - more members expressing recognition of the community's value




Challenges

- Streamlining processes
- Sustaining engagement and cohesion for a team with diverse expertise
- Establishing/tracking metrics for community engagement and impact

FUNDING

16%

Partners



84%

Grants -
federal or
government

Funding Streams

- 84% from the US National Institute on Aging
- 16% from private partner organizations
- AMP-AD 2.0 partners: National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), Food and Drug Administration (FDA), Pharmaceutical Industry: Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eisai Inc., Foundation for the NIH (FNIH), Alzheimer's Association, Gates Ventures

AMP-AD does not currently offer funding opportunities to community members.

ABOUT THIS PROFILE

This profile is part of a research project conducted by the Center for Scientific Collaboration and Community Engagement (CSCCE). You can find out more about the project, and view more community profiles, [on our website](#).

Information for this profile was submitted by Zoe Leanza, Communications Manager.

Last updated: 29 June 2021

Cite as: Center for Scientific Collaboration and Community Engagement (2021) CSCCE Community Profile: Accelerating Medicines Partnership in Alzheimer's Disease (AMP-AD). Woodley, Pratt, Kobilka, and Leanza doi: [10.5281/zenodo.5014074](https://doi.org/10.5281/zenodo.5014074)